Melatonin-Based Therapeutics for Atherosclerotic Lesions and
Beyond: Focusing on Macrophage Mitophagy
Amir Ajoolabady1,2, David J.
McClements3, Yaguang Bi2, Gregory
Y.H Lip4, Des R. Richardson5,6,7,
Daniel J. Klionsky8*, Russel J.
Reiter9*, and Jun Ren2,10*
1Center for Cardiovascular Research and Alternative
Medicine, University of Wyoming College of Health Sciences, Laramie, WY
82071 USA; 2Shanghai Institute of Cardiovascular
Diseases, Department of Cardiology, Zhongshan Hospital Fudan University,
Shanghai 200032, China; 3Department of Food Science,
University of Massachusetts Amherst, Amherst, MA, 01003, USA;4University of Liverpool Institute of Ageing and
Chronic Disease, Liverpool Centre for Cardiovascular Science, Liverpool,
United Kingdom of Great Britain and Northern Ireland;5Molecular Pharmacology and Pathology Program,
Department of Pathology and Bosch Institute, University of Sydney,
Sydney, New South Wales 2006, Australia; 6Department
of Pathology and Biological Responses, Nagoya University Graduate School
of Medicine, Nagoya 466-8550, Japan; 7Centre for
Cancer Cell Biology and Drug Discovery, Griffith Institute for Drug
Discovery, Griffith University, Nathan, Brisbane, Queensland 4111,
Australia; 8Life Sciences Institute and Departments of
Molecular, Cellular and Developmental Biology and Biological Chemistry,
University of Michigan, Ann Arbor 48109, USA;9Department of Cellular and Structural Biology,
University of Texas Health Science Center, San Antonio, TX, USA;10Department of Laboratory Medicine and Pathology,
University of Washington, Seattle, WA, 98195 USA